Initial Order for MuGard at Access Pharma (OTCBB: ACCP)
Posted by Mike Sweeney on Tue, Sep 14, 2010 @ 01:11 PM
Hard work pays off. It is somewhat rare to see a small BioPharm company sell a product as many are sold off to Big Pharma before they reach a commercial market launch. Today, Access Pharma (OTCBB: ACCP) received an order for $700,000 of their MuGard product from BioScrip (Nasdaq:BIOS), its specialty distribution partner. In an ACCP Press Release today, the Company stated that BioScrip's initial purchase order of MuGard will provide inventory for their various distribution channels to support the Company's first phase of its product launch for MuGard. Access Pharmaceuticals has inventory on hand and will begin shipping product to BioScrip immediately. MuGard is an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiation and/or chemotherapy
Jeffrey Davis, CEO of Access Pharmaceuticals stated in a press release:
"After months preparing for the official North American MuGard launch, this commercial order represents a significant milestone as it marks Access' first sales of MuGard in the US,With the help of our partners, especially BioScrip, we continue to broaden our reach within the medical community to further strengthen MuGard's position as the optimal treatment option for oral mucositis currently on the market."
ACCP has signed two distribution and marketing agreements in the US, with BioScrip and iMedicor/DMS. BioScrip is a leader in comprehensive pharmacy services, provides nationwide distribution for MuGard with its extensive physician relationships, 30+ top metro BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.